Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (April 2024)
24 slides from Island Pharmaceuticals's investor presentation, Apr 22, 2024
Slide 1: ASX Announcement: Island presentation for Asia BIO partnering conference and roadshow
22 April 2024 ASX Announcement Island presentation for Asia BIO partnering conference and Hong Kong / Singapore roadshow MELBOURNE Australia, 22 April 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to release a copy of t
Slide 2: About Island Pharmaceuticals
About Island Pharmaceuticals Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well- established safety profile, being repurposed for the prevention and treatment of den
Slide 3: Combatting Urgent Viral Disease Threats with a Key Focus on Dengue Fever
COMBATTING URGENT VIRAL DISEASE THREATS WITH A KEY FOCUS ON DENGUE FEVER APRIL 2024 (ASX: ILA) ISLAND PHARMACEUTICALS 1 APRIL 2024
Slide 4: Disclaimer
DISCLAIMER This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financial product advice "esti
Slide 5: Island Pharmaceuticals is a drug repurposing company focused on antivirals
Island Pharmaceuticals (ASX: ILA) is a drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases ISLAND PHARMACEUTICALS 3 APRIL 2024
Slide 6: Island at a Glance
ISLAND AT A GLANCE Dengue infects up to Major market Positive results in 400m per year* potential aggressive models Now endemic in more than 100 ISLA-101 has potential to address Of animal and human cellular countries, as well as previously mosquito-borne diseases, which are models of dengue fever a
Slide 7: About half of the world's population is now at risk of dengue
“About half of the world's population is now at risk of dengue with an estimated 100–400 million infections occurring each year” World Health Organisation, 17 March 2023 ISLAND PHARMACEUTICALS 5 APRIL 2024
Slide 8: Dengue in Singapore
DENGUE IN SINGAPORE Source 2 Source 1 Article sources: 1. https://www.straitstimes.com/singapore/health/dengue-cases-on-the-up-in-singapore-patients-say-the-illness-can-be- dreadful#:~:text=Already%2C%20more%20than%205%2C500%20people,were%20six%20deaths%20that%20year 2. https://www.precisionvaccinat
Slide 9: Dengue is a Widespread Issue
DENGUE IS A WIDESPREAD ISSUE Dengue outbreaks occurred in many countries of the world in the Americas, Africa, the Middle East, Asia, and the Pacific Islands HealthMap: recent reports of local or imported dengue cases https://www.healthmap.org/dengue/en - visited April 17, 2024 ISLAND PHARMACEUTICAL
Slide 10: Dengue in 2050 – A Global Disease
DENGUE IN 2050 – A GLOBAL DISEASE Prediction based on projections of future temperatures, rainfall, and mosquito populations Europe USA Australia NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford - https://earthobservatory.nasa.gov/features/disease-v
Slide 11: Commercial Opportunity
COMMERCIAL OPPORTUNITY ISLA-101 has potential as both a prophylactic and therapeutic Travelers Military National Outbreaks The malaria market, expected Partnering with army (CRADA Millions of patients in Latin to reach US$1B by 20261, is in place) for Phase 2a clinical America offer potential for ex
Slide 12: Introducing ISLA-101
Introducing ISLA-101 ISLAND PHARMACEUTICALS 10 APRIL 2024
Slide 13: ISLA-101 Broad Activity Evident
ISLA-101 BROAD ACTIVITY EVIDENT Demonstrated activity against flaviviruses (a subgroup of arboviruses) in multiple models of infection Dengue • In in-vitro models using fresh human cells, ISLA-101 has 1-4 demonstrated broad anti-viral activity • In animal models, ISLA-101 is protective in dengue fev
Slide 14: ISLA-101 Prevents Animal Deaths from Lethal Dengue
ISLA-101 PREVENTS ANIMAL DEATHS FROM LETHAL DENGUE ISLA-101 has also been shown to be protective in animal models of both dengue and Zika Virus. Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Fraser et al. J. Infect. Dis 2014 ISLAND PHARMACEU
Slide 15: Single Ascending Dose Study Now Complete
SINGLE ASCENDING DOSE STUDY NOW COMPLETE • Island completed a 24-subject Single Ascending Dose study for ISLA-101 in early 2024 • Study outcomes were highly positive: ISLA-101 was shown to be safe and well tolerated Data analysis showed required levels of ISLA-101 concentration in the blood were
Slide 16: ISLA-101 Development Milestones
ISLA-101 DEVELOPMENT MILESTONES • With data from the Single Ascending Dose study in hand, Island now plans to interact with the US FDA to discuss the study outcomes and strategies for how to maximise the data obtained from the PEACH* study • The PEACH study protocol may then be amended based on FDA
Slide 17: Why Dengue Diseases?
WHY DENGUE DISEASES? Significant unmet need for disease with increasing incidence ISLAND PHARMACEUTICALS 15 APRIL 2024
Slide 18: Limited Available Solutions
LIMITED AVAILABLE SOLUTIONS Deformities in babies from mothers with Zika 400 million ISLAND PHARMACEUTICALS 16 APRIL 2024
Slide 19: Building Our Pipeline
BUILDING OUR PIPELINE • In addition to ISLA-101, Island is exploring the acquisition or in-licensing of new drug candidates • Specific screening and scoring criteria being applied, based in part on the following criteria: • small molecule program • anti-viral • eligible for a Priority Review Voucher
Slide 20: Board and Corporate Snapshot
BOARD AND CORPORATE SNAPSHOT Corporate snapshot Key data points Dr Paul MacLeman Dr David Foster Dr David Brookes Mr Albert Hansen Dr Anna Lavelle Executive Chairman Managing Director Non-Executive Director Non-Executive Director Non-Executive Director Dr Paul MacLeman brings Dr Foster has 25+ years
Slide 21: Other Key Team Members
OTHER KEY TEAM MEMBERS Bobbi Drais Nick McCoy Senior Regulatory Consultant Vice President Clinical Product Development Bobbi is a dynamic global leader with an impressive track record spanning Nick is an experienced clinical research professional with a demonstrated over 25 years in regulatory affai
Slide 22: Scientific Advisory
SCIENTIFIC ADVISORY SLIDE Dr Leigh Farrell Prof Stephen Thomas MD Dr Amy Patick Leigh has over 30 years’ experience in the Professor Stephen Thomas, MD has an international Amy Patick is a scientific consultant with deep biotechnology and pharmaceutical industry and is leadership role as Lead Princi
Slide 23: Upcoming Milestones
UPCOMING MILESTONES H1 FY 2024 (Jul – Dec 2023; Completed H2 FY 2024 (Jan – Jun 2024) H1 FY 2025 Completed) Investigational New Drug • Key US and Australian • Dose final Single • Initiate PEACH trial application for ISLA-101 patents granted for ISLA-101 Ascending Dose study PEACH study opens subject
Slide 24: Island Pharmaceuticals
Island Pharmaceuticals (ASX: ILA) islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ISLAND PHARMACEUTICALS 22 APRIL 2024
Island Pharmaceuticals — Investor Presentation (April 2024) on 6ix